Stock comparison
Innoviva
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
INVA
Innoviva
Market cap
$1.66B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
United Therapeutics UTHR
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | INVA | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 51C | 71B | UTHR |
| Benjamin Graham | 50C | 76B | UTHR |
| Philip Fisher | 44D | 76B | UTHR |
| Peter Lynch | 16F | 62C | UTHR |
| Joel Greenblatt | 32F | 46D | UTHR |
| Charlie Munger | 47D | 64C | UTHR |
| Terry Smith | 46D | 64C | UTHR |
Side-by-side metrics
| Metric | INVA | UTHR |
|---|---|---|
| Market cap | $1.66B | $24.13B |
| P/E (TTM) | 3.3x | 19.2x |
| EV/EBIT | 8.6x | 15.2x |
| ROIC (TTM) | 2.93% | 18.81% |
| Gross margin | 76.2% | 86.58% |
| Net margin | 118.91% | 40.61% |
| Revenue CAGR 5y | 2.06% | 17.22% |
| EPS CAGR 5y | 5.54% | 29.84% |
| Debt / Equity | 0.2x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
INVA leads on
- P/E (TTM)3.3xvs 19.2x+83%
- Net margin118.91%vs 40.61%+66%
- EV/EBIT8.6xvs 15.2x+43%
UTHR leads on
- Debt / Equity-vs 0.2x+100%
- Market cap$24.13Bvs $1.66B+93%
- Revenue CAGR 5y17.22%vs 2.06%+88%
- ROIC (TTM)18.81%vs 2.93%+84%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.